According to published statistics, heart disease and stroke are the leading causes of hospitalization. Further, one third of all men and women in Canada die from cardiovascular disease (CVD). It is therefore one of the most important disease areas and clinical challenges for family physicians to understand and effectively manage.
As a leading medical centre of cardiovascular excellence and part of the University Health Network in Toronto, The Peter Munk Cardiac Centre has dedicated multidisciplinary teams which address the entire spectrum of CVD from innovative cellular research to its translation for improved clinical outcomes and collaborations in enhancing patient care with our local community partners. In combination with new and advanced techniques in diagnostic imaging and more effective intervention, these innovations are radically transforming the treatment of cardiovascular disease.
The integrative team philosophy of the Peter Munk Cardiac Centre extends to the critical clinical and communication links with our community partners, especially family physicians, who entrust the Centre with the care of their patients. There is increasing recognition of the need to continue strengthening these links and the continuum of health care provision between our community partners and the Peter Munk Cardiac Centre.
With this goal in mind, we extend this special invitation for you to attend our upcoming 9th Annual Peter Munk Cardiovascular Symposium on January 20-21, 2017. Please note that attendance is limited, so we ask that you register as soon as possible while space is still available.
The overall aim of this symposium is to highlight optimal assessment and management of patients at risk for the complications of CVD, through discussion of the latest thinking and best practices for office-based patient assessment with emphasis on an integrative patient-focused approach.
After attending this symposium, you will be better able to:
- Describe the importance of stress and a stress management program in heart disease
- Describe the role of exercise in heart failure
- Provide an update on nutrition for cardiovascular health
- Review the latest indications for surgical intervention in coronary artery disease
- Describe the progress in stem cell therapy for arterial disease
- Analyze the role of surgical and minimally interventional approaches to aortic and valve disease
- Describe the current approach to use of oral anticoagulants
- Discuss current knowledge in the diagnosis and management of chemotherapy induced cardiac disease
- Summarize key aspects of secondary prevention of ischemic coronary events
- Family Practitioners
- Nurses and Allied Health professionals involved in cardiovascular patient care
The College of Family Physicians of Canada
This Group Learning program meets the certification criteria of the College of Family Physicians of Canada and has been certified by Continuing Professional Development, Faculty of Medicine, University of Toronto, for up to 11.5 Mainpro+ credits.
Royal College of Physicians and Surgeons of Canada
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, approved by Continuing Professional Development, Faculty of Medicine, University of Toronto, up to a maximum of (11.5 hours).
The American Medical Association – AMA PRA Category 1 Credit™
Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme
It is the policy of University of Toronto, Faculty of Medicine, Continuing Professional Development to ensure balance, independence, objectivity, and scientific rigor in all its individually accredited or jointly accredited educational programs. Speakers and/or planning committee members, participating in University of Toronto accredited programs, are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships within the last FIVE (5) years with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of facts. It remains for the audience to determine whether the speaker's outside interests may reflect a possible bias in either the exposition or the conclusions presented.